Symptoms of depression · depression in adults
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
1 finding from 1 review
Quality of life · depression in adults
1 finding from 1 review
Adverse events · depression in adults
1 finding from 1 review
Adverse events · depression in adults
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
1 finding from 1 review
Quality of life · depression in adults
1 finding from 1 review
Symptoms of depression · depression in adults
1 finding from 1 review
Secondary outcome: acceptability of treatment · depression in adults
1 finding from 1 review
Quality of life · depression in adults
1 finding from 1 review
Symptoms of depression · depression in adults
1 finding from 1 review
Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
1819 participants
Moderate
Barnes Akathisia Scale LOCF at week 12 A physician‐assessed rating scale to assess the severity of drug‐induced akathisia Scale from 0 to 14 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
Abnormal Involuntary Movement Scale LOCF at week 12 A physician‐administered rating scale with 12 items to measure tardive dyskinesia Scale from 0 to 40 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
634 participants
Low
Simpson Angus Scale LOCF at week 12 A physician‐administered rating scale to measure drug‐induced Parkinsonism Scale from 0 to 40. · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.7 [1.23, 2.34]
1230 participants
Moderate
Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.03 [0.95, 1.12]
2216 participants
Moderate
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Akathisia Participant report · patients with an acute manic or mixed episode
Aripiprazole leads to higher akathisia Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 3.16 [2.25, 4.43]
2305 participants
High
Nausea · patients with an acute manic or mixed episode
Aripiprazole leads to higher nausea Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 1.5 [1.2, 1.88]
2305 participants
High